Skip Navigation
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

National Institute of Environmental Health Sciences

Use this QR code to view the newest version of this document
Use this QR code to view the newest version of this document

Your Environment. Your Health.

Publication Detail

Title: Genetic variations in the Hippo signaling pathway and breast cancer risk in African American women in the AMBER Consortium.

Authors: Zhang, Jianmin; Yao, Song; Hu, Qiang; Zhu, Qianqian; Liu, Song; Lunetta, Kathryn L; Haddad, Stephen A; Yang, Nuo; Shen, He; Hong, Chi-Chen; Sucheston-Campbell, Lara; Ruiz-Narvaez, Edward A; Bensen, Jeannette T; Troester, Melissa A; Bandera, Elisa V; Rosenberg, Lynn; Haiman, Christopher A; Olshan, Andrew F; Palmer, Julie R; Ambrosone, Christine B

Published In Carcinogenesis, (2016 10)

Abstract: The Hippo signaling pathway regulates cellular proliferation and survival, thus exerting profound effects on normal cell fate and tumorigenesis. Dysfunction of the Hippo pathway components has been linked with breast cancer stem cell regulation, as well as breast tumor progression and metastasis. TAZ, a key component of the Hippo pathway, is highly expressed in triple negative breast cancer; however, the associations of genetic variations in this important pathway with breast cancer risk remain largely unexplored. Here, we analyzed 8309 germline variants in 15 genes from the Hippo pathway with a total of 3663 cases and 4687 controls from the African American Breast Cancer Epidemiology and Risk Consortium. Odds ratios (ORs) were estimated using logistic regression for overall breast cancer, by estrogen receptor (ER) status (1983 ER positive and 1098 ER negative), and for case-only analyses by ER status. The Hippo signaling pathway was significantly associated with ER-negative breast cancer (pathway level P = 0.02). Gene-based analyses revealed that CDH1 was responsible for the pathway association (P < 0.01), with rs4783673 in CDH1 statistically significant after gene-level adjustment for multiple comparisons (P = 9.2×10(-5), corrected P = 0.02). rs142697907 in PTPN14 was associated with ER-positive breast cancer and rs2456773 in CDK1 with ER-negativity in case-only analysis after gene-level correction for multiple comparisons (corrected P < 0.05). In conclusion, common genetic variations in the Hippo signaling pathway may contribute to both ER-negative and ER+ breast cancer risk in AA women.

PubMed ID: 27485598 Exiting the NIEHS site

MeSH Terms: Antigens, CD; CDC2 Protein Kinase/genetics*; Cadherins/genetics*; Estrogen Receptor alpha/genetics*; Female; Gene Expression Regulation, Neoplastic; Genetic Association Studies; Genetic Predisposition to Disease; Humans; Neoplasm Metastasis; Neoplasm Proteins/genetics; Neoplastic Stem Cells/metabolism; Neoplastic Stem Cells/pathology; Polymorphism, Single Nucleotide; Protein Tyrosine Phosphatases, Non-Receptor/genetics*; Protein-Serine-Threonine Kinases/genetics; Risk Factors; Signal Transduction; Triple Negative Breast Neoplasms/genetics*; Triple Negative Breast Neoplasms/pathology

Back
to Top